Next Article in Journal
Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer
Next Article in Special Issue
Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer’s Disease
Previous Article in Journal
The Interaction of Fluorinated Glycomimetics with DC-SIGN: Multiple Binding Modes Disentangled by the Combination of NMR Methods and MD Simulations
Review

Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring

1
Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
2
Department of Pharmacy, Nutritional and Health Sciences, University of Calabria, Arcavacata di Rende, 87100 Cosenza, Italy
3
Structural and Molecular Microbiology, Structural Biology Research Center, VIB, 1050 Brussels, Belgium
4
Structural Biology Brussels, Vrije Universiteit, 1050 Brussels, Belgium
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors jointly supervised this work.
Pharmaceuticals 2020, 13(8), 180; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13080180
Received: 18 June 2020 / Revised: 27 July 2020 / Accepted: 3 August 2020 / Published: 4 August 2020
Cells can communicate through special “messages in the bottle”, which are recorded in the bloodstream inside vesicles, namely exosomes. The exosomes are nanovesicles of 30–100 nm in diameter that carry functionally active biological material, such as proteins, messanger RNA (mRNAs), and micro RNA (miRNAs). Therefore, they are able to transfer specific signals from a parental cell of origin to the surrounding cells in the microenvironment and to distant organs through the circulatory and lymphatic stream. More and more interest is rising for the pathological role of exosomes produced by cancer cells and for their potential use in tumor monitoring and patient follow up. In particular, the exosomes could be an appropriate index of proliferation and cancer cell communication for monitoring the minimal residual disease, which cannot be easily detectable by common diagnostic and monitoring techniques. The lack of unequivocal markers for tumor-derived exosomes calls for new strategies for exosomes profile characterization aimed at the adoption of exosomes as an official tumor biomarker for tumor progression monitoring. View Full-Text
Keywords: exosomes; cancer; liquid biopsy; tumor circulome; tumor monitoring; tumor derived exosomes hematological malignancies; minimal residual disease exosomes; cancer; liquid biopsy; tumor circulome; tumor monitoring; tumor derived exosomes hematological malignancies; minimal residual disease
Show Figures

Graphical abstract

MDPI and ACS Style

Maisano, D.; Mimmi, S.; Russo, R.; Fioravanti, A.; Fiume, G.; Vecchio, E.; Nisticò, N.; Quinto, I.; Iaccino, E. Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Pharmaceuticals 2020, 13, 180. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13080180

AMA Style

Maisano D, Mimmi S, Russo R, Fioravanti A, Fiume G, Vecchio E, Nisticò N, Quinto I, Iaccino E. Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Pharmaceuticals. 2020; 13(8):180. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13080180

Chicago/Turabian Style

Maisano, Domenico, Selena Mimmi, Rossella Russo, Antonella Fioravanti, Giuseppe Fiume, Eleonora Vecchio, Nancy Nisticò, Ileana Quinto, and Enrico Iaccino. 2020. "Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring" Pharmaceuticals 13, no. 8: 180. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13080180

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop